ALX Oncology Holdings Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 45.47 million compared to USD 30.71 million a year ago. Basic loss per share from continuing operations was USD 0.93 compared to USD 0.75 a year ago.

For the full year, the company reported net loss was USD 160.81 million compared to USD 123.48 million a year ago. Basic loss per share from continuing operations was USD 3.74 compared to USD 3.03 a year ago. Diluted loss per share from continuing operations was USD 3.74 compared to USD 3.03 a year ago.